

# **Quality Assurance (QA) for Health Products**

#### **QA Notice**

| IN Nº 2024-01           | Communication related to the recall initiated by Masimo<br>Corporation (USA) on certain Masimo Rad-G® Pulse Oximeter |
|-------------------------|--|
| Version 1 – 02 May 2024 | devices.   |

#### Addressees

- Through Health Product Management (HPM) specialists, all Principal Recipients (PR) reporting procurement of the impacted product financed by the Global Fund.
- Any procurer, buyer reporting procurement of the impacted product financed by the Global Fund.

#### Purpose

The Global Fund Quality Assurance and Compliance Team is issuing this QA Notice to share information on a recall related to certain Masimo Rad-G® Pulse Oximeter devices distributed worldwide by the manufacturer Masimo Corporation (USA).

## Identification of the product(s) and manufacturer

| Name of Manufacturer(s)                                      | Masimo Corporation<br>52 Discovery<br>Irvine CA 92618-3105<br>United States of America  |  |
|--|---|--|
| Commercial / Brand Name(s)                                   | Masimo Rad-G® Pulse Oximeter  |  |
| Formulation  | Not applicable  |  |
| Reference Number (REF) and<br>Unique Device Identifier (UDI) | <ul> <li>Masimo Rad-G® Pulse Oximeter with temperature<br/>(W/Sensor), REF: 9210, UDI: (01)00843997008013</li> <li>Masimo Rad-G® Pulse Oximeter (W/Patient Cable),<br/>REF: 9895, UDI: (01)00843997013789</li> <li>Masimo Rad-G® Pulse Oximeter (W/Patient Cable),<br/>REF: 9849, UDI: (01)00843997000666</li> <li>Masimo Rad-G® Pulse Oximeter (W/Sensor), REF:<br/>9847, UDI: (01)00843997013284</li> </ul> |  |
| Serial number(s)   | Multiple  |  |
| Manufacturing / Release Date                                 | Between June 2022 and December 2022   |  |



## Background

On 15 April 2024 the Global Fund Quality Assurance and Compliance Team received information on an urgent recall initiated by Masimo Corporation related to certain Rad-G® Pulse Oximeter devices.

## Nature of defect(s)

| Details of defect or problem                                   | Masimo Corporation (USA) identified certain of its Rad-G®<br>Pulse Oximeter devices powering off and on without<br>pressing the power button. Masimo Corporation's<br>investigation identified an issue that can result in an<br>unintentional change in the power state.   |  |
|--|---|--|
|  | If the device powers off unexpectedly, it could result in a loss<br>of patient monitoring and consequentially delayed patient<br>care.  |  |
| Is there any evidence or suspicion of a risk to user/ patient? | Yes, if the device powers off unexpectedly, it could result in<br>a loss of monitoring, which could potentially result in a delay<br>in patient care.   |  |
| Extent of the problem (e.g. No. of batches).                   | Please refer to Masimo Corporation notice<br>(https://professional.masimo.ca/globalassets/assets/pdf/_res<br>ources/plf-1484a-product-flash-product-recall-for-select-rad-<br>g-and-rad-g-temperature-devices-global_final_for-web.pdf),                                    |  |
|  | and the U.S. FDA Medical Device Recalls Database<br>(https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/r<br>es.cfm?start_search=1&event_id=94170) for a list of the<br>serial numbers of the Masimo Rad-G® Pulse Oximeter<br>devices subject to this Quality Notice. |  |
| Extent of distribution of the product / batch (es).            | Worldwide   |  |
| Number of patients potentially impacted                        | Not identified  |  |

## Action/Investigations to be taken

Addressees are advised to identify and promptly remove impacted Masimo Rad-G® Pulse Oximeter devices from use and contact the Technical Services of Masimo Corporation (https://professional.masimo.com/company/global-services/technical-services/).



### **Users and/or Patients**

Patients and/or users who have experienced any adverse reaction or quality problems with the use of the impacted product may report this to the relevant National Regulatory Authorities, manufacturer and the Global Fund Health Product Management Specialist.

### **Transmission of QA Notice**

This QA Notice needs to be passed on to all those who need to be aware within your organization and/or to any organization where the potentially affected products have been transferred.

Please maintain awareness of this QA Notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

### Contacts

This QA Notice does not require a specific written response from PRs and procurers to the Global Fund.

PRs and procurers should copy the Global Fund's Health Products Management Specialist on correspondences regarding the matter for follow-up.

Please direct the respective answers and any questions about this matter to the technical contact listed below.

| Organization | Name / Function   | E-mail address                  |  |
|--------------|---|---------------------------------|--|
| Global Fund  | Your respective HPM specialist for the portfolio                  |                                 |  |
| Global Fund  | Xiao Xiao, Specialist, MDs & PPEs<br>Quality Assurance Specialist | xiaoxiao.ding@theglobalfund.org |  |